Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer

In the new era of cancer immunotherapy, clinical research has uncovered diverse and unpredictable immune‐related adverse events. Here, we report the first case of pembrolizumab‐induced myasthenia gravis (MG) and myositis in a patient with lung cancer. The patient developed symptoms after the second...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibino, Makoto, Maeda, Kazunari, Horiuchi, Shigeto, Fukuda, Minoru, Kondo, Tetsuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079932/
https://www.ncbi.nlm.nih.gov/pubmed/30094028
http://dx.doi.org/10.1002/rcr2.355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079932/
https://www.ncbi.nlm.nih.gov/pubmed/30094028
http://dx.doi.org/10.1002/rcr2.355

Ejemplares similares